Scemblix Европска Унија - Румунски - EMA (European Medicines Agency)

scemblix

novartis europharm limited - asciminib hydrochloride - leucemie, mielogenă, cronică, bcr-abl pozitivă - agenți antineoplazici - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Vanflyta Европска Унија - Румунски - EMA (European Medicines Agency)

vanflyta

daiichi sankyo europe gmbh - quizartinib dihydrochloride - leucemie mieloidă - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.